- Short Report
- Open Access
CDK9 inhibition strategy defines distinct sets of target genes
BMC Research Notes volume 7, Article number: 301 (2014)
CDK9 is the catalytic subunit of the Positive Transcription Elongation Factor b (P-TEFb), which phosphorylates the CTD of RNAPII and negative elongation factors enabling for productive elongation after initiation. CDK9 associates with T-type cyclins and cyclin K and its activity is tightly regulated in cells at different levels. CDK9 is also the catalytic subunit of TAK (Tat activating Kinase), essential for HIV1 replication. Because of CDK9′s potential as a therapeutic target in AIDS, cancer, inflammation, and cardiomyophathy it is important to understand the consequences of CDK9 inhibition. A previous gene expression profiling study performed with human glioblastoma T98G cells in which CDK9 activity was inhibited either with a dominant negative mutant form of CDK9 (dnCDK9) or the pharmacological inhibitor Flavopiridol unveiled striking differences in gene expression effects. In the present report we extended these studies by (1) using both immortalized normal human fibroblasts and primary human astrocytes, (2) eliminating potential experimental variability due to transduction methodology and (3) also modulating CDK9 activity with siRNA.
Striking differences in the effects on gene expression resulting from the strategy used to inhibit CDK9 activity (dnCDK9 or FVP) remain even when potential variability due to viral transduction is eliminated. siRNA mediated CDK9 knockdown in human fibroblasts and astrocytes efficiently reduced CDK9 expression and led to potent changes in gene expression that exhibit little correlation with the effects of dnCDK9 or FVP. Interestingly, HEXIM1 a validated CDK9 target gene, was found to be potently downregulated by dnCDK9, FVP and siCDK9, but the cluster of genes with expression profiles similar to HEXIM1 was small. Finally, cluster analysis of all treatments revealed higher correlation between treatments than cell type origin.
The nature of the strategy used to inhibit CDK9 profoundly affects the patterns of gene expression resulting from CDK9 inhibition. These results suggest multiple variables that affect outcome, including kinetics of inhibition, potency, off-target effects, and selectivity issues. This is particularly important when considering CDK9 as a potential target for therapeutic intervention.
CDK9 is the catalytic subunit of the positive Transcription Elongation Factor b (P-TEFb), which associates with T-type cyclins (T1 and T2) and cyclin K regulatory subunits (reviewed in [1–3]). These complexes promote transcriptional elongation via phosphorylation of the C-terminal domain (CTD) of the large subunit of RNA polymerase II (RNAPII) and subunits of the negative elongation factors DSIF (DRB Sensitivity Inducing Factor) and NELF (Negative Elongation factor). CDK9 preferentially triggers phosphorylation of Pro-directed Ser/Thr sites . Phosphorylation of RNAPII by CDK9 has been reported to occur preferentially on Ser-2 rather than Ser-5 on the seven-amino acid repeats that form the CTD . However, we have previously shown that in at least two cell lines inhibition of CDK9 activity with flavopiridol (FVP) or a dominant negative mutant of CDK9 results in inhibition of both Ser-2 and Ser-5 phosphorylation on the CTD of RNAPII [6, 7]. Many genes are regulated at the elongation rather than the initiation phase of transcription and P-TEFb is recruited by numerous transcription factors near the transcription start sites of many of these promoters. CDK9 inhibition has been studied as a potential therapeutic target for multiple pathologies, including, AIDS, cardiac hypertrophy, inflammation and cancer ([8–14]). We and others have determined the effect of inhibiting CDK9 activity in global gene expression by different means including pharmacological inhibitors [6, 7, 15, 16], a dominant negative mutant of CDK9  and RNA interference targeted to various P-TEFb subunits [17–19] using a variety of cells. Effects on gene expression have been clearly seen in all instances, but it is unclear if the differential patterns of gene expression reflect cell type and/or signal specific differences, or alternatively the differences are due to the kinetics of CDK9 inhibition, potency or the potential off target effects specific to each methodology. Off target effects may include lack of selectivity in pharmacological approaches, anti-viral effects due to viral transduction in dominant negative and RNA interference approaches, as well as squelching effects in both dominant negative and RNA interference approaches.
In this study we sought to compare global changes in gene expression resulting from inhibition of CDK9 activity by different means in hTERT immortalized normal human fibroblasts and primary astrocytes, as well as compare them to previous data obtained using T98G glioblastoma cells .
Results and discussion
We had previously reported differential effects on gene expression in human glioblastoma T98G cells when CDK9 activity was either inhibited pharmacologically with FVP or with a dominant negative form of CDK9 (dnCDK9) expressed from an adenoviral vector . Changes in mRNA expression were determined via Affymetrix microarray analysis. The effects of FVP in mRNA expression were consistent with global inhibition of transcription, whereas inhibition of CDK9 activity with dnCDK9 had more restricted and distinctive effects, with the expression of slightly more genes being upregulated that downregulated . These data suggested that the broader and more potent inhibitory effects of FVP in transcription could be due to the inhibition of other CTD kinases. This is conceivable, because although FVP IC50 for CDK9 is 4 fold lower than for other tested CDKs, the IC50 for several other CDKs [13, 20], including some with the ability to phosphorylate the CTD of RNAPII has not been reported. However, it must be considered that the differences in the mechanisms of CDK9 inhibition, as well as the inhibition kinetics and potency may explain at least some of the distinctive gene expression effects. While FVP inhibits CDK9 activity very potently and rapidly, inhibition with dnCDK9 is much slower, depending on expression of the dominant negative mutant and replacement of endogenous CDK9 from T-type cyclin complexes within the cell. Moreover, since transduction of cells with adenoviruses has an effect on gene expression , we could not rule out that vector effects contributed to the differences in gene expression between FVP and dnCDK9.
Effects of dnCDK9 and FVP in adenovirally transduced human BJ-TERT fibroblasts
To extend this study, we selected a non-transformed cell line of normal human fibroblasts immortalized with human telomerase (hTERT), designated BJ-TERT fibroblasts. In our hands these cells have proliferation properties similar to those exhibited by parental non-immortal BJ fibroblasts [22, 23]. To eliminate the effects of transduction as a cause of differential effects in gene expression, all cells were transduced identically using the inducible Adeno-X™ Tet-Off system from Clontech carrying a dnCDK9 transgene under a tetracycline repressible promoter. BJ-TERT cells were transduced with the same sets of adenoviruses (Ad-X-dnCDK9 and Ad-Tet-off). Tetracycline was added to the media of the control cells (tet-DN), as well as cells to be treated with FVP (FVP/DN/tet) to prevent expression of dnCDK9, while cells selected to express dnCDK9 were allowed to grow in the absence of tetracycline (DN, see methods). Under these experimental conditions, the baseline gene expression was the same in all samples prior to inhibition of CDK9 by different means. Forty-eight hours post-transduction, we analyzed the effects of CDK9 inhibition on phosphorylation of RNAPll on serine position 2 (Ser-2) and 5 (Ser-5) using specific antibodies (Figure 1A). CDK9 is thought to phosphorylate Ser-2 during transcription elongation, while CDK7 phosphorylates Ser-5 at initiation . However, and consistent with our previous observations using T98G cells , both Ser-2 and Ser-5 were found to be clearly dephosphorylated in BJ-TERT cells expressing dnCDK9 or treated with FVP (Figure 1A, compare lanes 1–2 and 5–10 to lanes 3–4). BJ-TERT fibroblasts transduced in parallel in the presence of tetracycline were treated with 300 nM FVP for the indicated last 4, 8 and 24 h prior to the 48 h collection time (under these conditions cells remain attached to the tissue culture dish and show no signs of overt cell death). FVP inhibited Ser-2 and Ser-5 phosphorylation at all time points more efficiently than dnCDK9. Consistent with its global inhibitory effect on transcription, the levels of endogenous CDK9 and, less prominently, cyclin T1 (24 h time point) were also downregulated by the FVP treatment (Figure 1A) and total protein concentration significantly decreased by the 24 h time point (data not shown). We also verified the inhibitory effects of dnCDK9 and FVP on the expression of HEXIM1, a gene known to be modulated by P-TEFb, which is very sensitive to CDK9 inhibition [6, 24]. As shown in Figure 1B, the HEXIM1 mRNA levels are downregulated by both dnCDK9 and FVP. The effects of overexpressing cyclin T1 and CDK9 were also monitored. No major effects were noticed in the phosphorylation of the CTD of RNAPII or the expression of HEXIM1 mRNA, as compared to control cells infected with Ad-Cre, expressing the Cre recombinase.
We next performed a global gene expression profiling of the effects of inhibiting CDK9 in BJ-TERT fibroblasts by using Affymetrix Human Gene 1.0 ST DNA arrays and total RNAs from the samples described above in triplicate. These arrays contain probes representing 28,869 different genes. RNAs were labeled, hybridized to microarrays and scanned as described in . Raw transcript intensity data were normalized and the expression value log2 ratio for each gene was computed between its treatment and corresponding control sample (tet/DN was the control for DN and the FVP/DN/Tet treatments; Ad-Cre (CR) was the control for Ad-T1/K9 (T1/K9); and ctr is the ratio of the two control treatments tet/DN vs. Ad-Cre (CR)). Principal component analysis demonstrates that all biological replicates cluster together (Additional file 1: Figure S1). We represented the average gene expression value between replicates as the average log2 ratio. Next, hierarchical cluster analysis was performed with the log2 ratios and visualized using by Java Tree View (Figure 1C). Gene array ratios for the three FVP treatments clustered together (correlation: 0.76-0.91), but exhibited much lower correlation with the dnCDK9 gene array ratios (correlation: 0.44). If only the probe sets that change two fold or more (log2 ratios ≤ -1 or ≥1) with at least one treatment are considered, this correlation increases slightly (0.50)(Figure 1C, right clusters). Interestingly, ectopic expression of P-TEFb subunits (cyclin T1 and CDK9) resulted in the marked upregulation of a small subset of genes, with mostly no effect on genes dramatically upregulated/downregulated by FVP or dnCDK9. Of note, the small subset of genes upregulated were highly enriched with interferon response genes, which could indicate that in virally transduced cells P-TEFb activity is limiting (Additional file 2: Figure S2). As expected, very little difference was observed in the expression profile of both control cell treatments: cells transduced with Ad-X-dnCDK9/Ad-Tet in the presence of tetracycline versus Ad-Cre (Figure 1C, ctr (tet/DN vs. CR), right array in all clusters).
Analysis of the probe sets that change approximately two fold or more (log2 ratios ≤ -1 or ≥1) upon dnCDK9 expression showed that 93 probe sets were downregulated and 32 were upregulated (Figure 2). The highest downregulation corresponded to HEXIM1 (log2 = -1.72043), confirming the sensitivity of HEXIM1 to CDK9 inhibition. As expected, FVP also potently inhibited HEXIM1 expression (log2 = -1.72494 to -3.22926). The highest probe set intensity in the dnCDK9 array was CDK9, an obvious expected result due to the ectopic expression of dnCDK9, as the probe set does not discriminate between dnCDK9 and endogenous CDK9. Of note, FVP inhibited the expression of endogenous CDK9. The correlation between the FVP arrays was 0.95 for the 4 and 8 h treatments and 0.84 with the 24 h treatment. It was also clear that the increase/decrease in gene expression with FVP was time dependent. The correlation between the FVP and dnCDK9 arrays was 0.57, noticeably higher than we had seen in our previous study using T98G cells . The lowest log2 ratio was -1.7 and the highest was 2.2, while the expression change range for FVP at 24 h was much higher (-5.4 to 4.2). Therefore, one cannot conclude that the effects of dnCDK9 are more or less potent than any of the FVP treatments for this set of genes but rather different.
Global effect on gene expression with loss of CDK9 function via siRNA
The observation that many of the genes more sensitive to dnCDK9 or FVP treatment are different suggest that one or both methods lack selectivity or have off target effects. For instance, FVP may inhibit other CDKs with roles in transcription in addition to CDK9, even at the concentrations used in this study. One could also envision dnCDK9 having additional effects unrelated to CDK9 inhibition resulting from squelching P-TEFb partners. Alternatively, the differences could be explained by the difference in kinetics of inhibition of FVP compared to dnCDK9. FVP acts very rapidly and potently, while inhibition by dnCDK9 occurs slowly, depending on expression and replacement of active complexes by inactive ones. In view of these results, we decided to broaden our study by reducing CDK9 expression via siRNA. This is a priori a very specific and selective method, as no other RNA sequences are targeted and, thus, other RNAPII CDKs should not be directly affected. BJ-TERT fibroblasts were transfected twice within 24 h with two independent siRNAs (103 and 104) and collected 72 h after the first transfection. We next determined the effect of each siRNA and their combination on CDK9 levels. Both 103 and 104 siRNAs efficiently knocked-down CDK9 mRNA and protein (Figure 3A), with little additional downregulation when both siRNAs were used in combination. As expected scramble siRNAs had no effect on CDK9 levels. However, in contrast to FVP and dnCDK9 treatments (Figure 1A), phosphorylation of Ser-2 and Ser-5 of the CTD of RNAPII were not visibly affected by either siCDK9 or their combination (Figure 3A). The effects of knocking-down CDK9 in global gene expression in BJ-TERT fibroblasts were determined using Affymetrix Human Gene 1.0 ST DNA arrays similarly as described for dnCDK9 and FVP treated cells. Cells were transfected in triplicate with each siCDK9 or combination or in duplicate with scramble siRNA. Cells were collected 72 h later to generate RNA probes (see Methods). About 650 probe sets exhibited changes in gene expression equal or larger than two fold (log2 ratios ≤ -1 or ≥1). A cluster analysis of genes that changed two fold or more with siCDK9 or dnCDK9 is shown in Figure 3B. The correlation between siCDK9 treatments was high (0.86-0.95). Both the 103 and 104 siRNAs exhibit some unique set of genes that were more potently affected, with the combination appearing to be additive for those genes. However, for genes that were commonly downregulated or upregulated by both siRNA separately, the combination mostly lacked additive effects (Figure 3B, side grey bars). This may reflect that both siRNAs knocked-down CDK9 to similar levels even when used in combination, as the total siRNA concentration was the same in all transfections. Surprisingly clustering analysis also revealed major differences between the effect of the siRNAs and dnCDK9 (correlation 0.15). For instance a large set of genes upregulated by dnCDK9 are not affected by either siRNA (bottom large cluster in the array). Similarly, the top of the array shows several genes potently downregulated by dnCDK9 that show minimal downregulation by siRNA. In addition, most of the genes upregulated by either 103, 104 or the combination of both are either not affected or downregulated by dnCDK9. While there is more agreement within the genes downregulated by the siRNAs, the overall comparison exhibits little similarity.
The effect of these siRNAs were also determined in primary human astrocytes. Cells were transfected in duplicate with siRNAs targeting CDK9 (103 and 104), scramble or mock transfected and cells were harvested 72 h later. As with BJ-TERT fibroblasts, 103 and 104, but not scramble knocked down CDK9 mRNA and protein (Figure 4A). RNA was prepared from transfected and untransfected cells for microarray analysis and data were analyzed as above. Untreated cells were analyzed in this experiment to determine whether any of the effects observed in siRNA transfected cells could be due to experimental manipulation. We observed that transfection had significant effects in the expression of interferon response genes as well as other genes. Transfection with one of the siRNAs directed to CDK9 (104) had additional effects on the expression of these genes, which were dramatically upregulated, but were not upregulated with the other siRNA directed to CDK9 (103). Elimination of those genes in clustering analysis allows focusing in the potentially regulated genes, defined as those affected by transfection with both 103 and 104, but not scr, as compared to untransfected cells (Figure 4B).
Finally, we combined all microarray data from this study and our previously published data using T98G cells  to perform hierarchical cluster analysis. Interestingly, this analysis shows that gene arrays cluster by treatment rather than cell type or transformation status (Figure 5A). Specifically, the FVP treatments of T98G and BJ-TERT fibroblasts clustered together, as did siRNA transfected cells or cells expressing dnCDK9. These data show that the type of treatment induces clear signatures shared in across cell types that are more prominent than cell type specific signatures that could result from inhibition of CDK9 by any methodology (Figure 5B).
In summary, it is clear that the strategy selected to inhibit CDK9 activity in cells contributes to the changes in gene expression observed and, thus, caution needs to be observed in the interpretation of data, especially when comparing results obtained using different strategies (Figure 5B). Because pharmacologic inhibitors such as FVP act rapidly (within minutes of treatment), the observed effects in gene expression are acute and more likely to be direct if the pharmacologic inhibitor is selective in cells. In our hands, FVP inhibits phosphorylation of RNAPII on both Ser-2 and Ser-5 (Figure 1), even when used for shorter periods of time . Also, using lower concentrations of FVP in cells did not result in significantly greater selectivity . So, it cannot be ruled out that the potency of FVP is in part due to inhibition of other CTD kinases with roles in transcriptional elongation and responsible for Ser-5 phosphorylation. On the other hand, it is also conceivable that CDK9 phosphorylates both Ser-2 and Ser-5 in cells, and this is consistent with the results obtained with dnCDK9, which inhibits phosphorylation of both. Surprisingly, we did not observe major changes in the phosphorylation state of both Ser-2 and Ser-5 upon CDK9 knockdown, which might suggest that in the absence of CDK9 other CDKs may act redundantly to maintain overall CTD phosphorylation in cells. It is anticipated that development of more selective pharmacologic inhibitors of CDK9 will help resolve the open questions in the future.
These observations are significant because CDK9 is being evaluated as a therapeutic target for a number of pathologies and the efficacy of treatments targeting CDK9 would be predicted to be highly variable depending on the approach used to inhibit CDK9 activity.
BJ-TERT fibroblasts are normal human BJ fibroblasts immortalized with human Telomerase Reserve Transcriptase (hTERT) . BJ-TERT fibroblasts were grown in Dulbecco’s Modification of Eagle’s Medium (DMEM) (Cellgro) supplemented with 10% Fetal Bovine Serum (FBS) (Sigma) and antibiotics at 37°C in 5% CO2. Normal human astrocytes (NHA) were purchased from Lonza and grown in astrocyte basal media (ABM™) plus growth factors (Lonza) at 37°C and 5% CO2 following manufacturer’s directions. NHA have a limited life-span, but can be expanded up to five passages.
CDK9 was pharmacologically inhibited by adding Flavopiridol (FVP) to the medium to a final concentration of 300 nM. FVP was dissolved in DMSO to generate a 10 mM stock and then diluted in PBS to 100 μM and added to the medium. Control cells were treated with the same concentration of DMSO (Dimethyl sulfoxide) dissolved in PBS. FVP treated cells were preinfected with Ad-T-dnCDK9 plus Adeno-X™ Tet-Off™ adenoviruses in the presence of tetracycline (tet/DN) to eliminate viral transduction as a variable in the comparison to dnCDK9 expressing cells (transduced with Ad-T-dnCDK9 plus Adeno-X™ Tet-Off™ in the absence of tetracycline (DN)). BJ-TERT fibroblasts were infected with Ad-T-dnCDK9 plus Adeno-X™ Tet-Off™ adenoviruses (dn) in the presence or absence of tetracycline (tet) essentially as previously described  and then treated with FVP for 8, 4 and 24 h. Double stranded siRNAs were obtained from Ambion and had the following sense sequences: 103, 5′-GGUGCUGAUGGAAAACGAGtt-3′ and 104, 5′-GGAGAAUUUUACUGUGUUUtg-3′. The scrambled siRNA, Scr, 5′- AAUUCUCCGAACGUGUCACGU-3′ was purchased from Qiagen. BJ-TERT fibroblasts (0.5 × 106) were seeded in 10 cm plates 14 h prior to transfection. SiRNAs were transfected with Dharmafect using manufacturer-established protocols. The Dharmafect/siRNA/antibiotic free medium mix was incubated for 20 min at room temperature and added to cells re-fed with fresh antibiotic free medium. NHA (1 × 106) were transfected with 50 nM siRNA in the presence of 15 μL Lipofectamine RNAimax (Life Technologies) in serum free media (Optimem, Life Technologies). Media was changed 6 hours later and cells were collected to process for analysis 72 hours post-transfection.
Protein and RNA analyses
Cells were lysed with ice-cold lysis buffer (50 mM Tris–HCl (pH 7.4), 5 mM EDTA, 250 mM NaCl, 50 mM NaF, 0.1 mM Na3VO4, 0.1% Triton X-100, 2 mM PMSF, 4 μg/ml aprotinin, 10 μg/ml leupeptin, and 40 μg/ml pepstanin). Protein concentration was determined using the BioRad protein reagent and BSA to generate a standard curve, with all protein sample replicates reading in the linear range. Proteins were resolved by 8% polyacrylamide/SDS gel electrophoresis, and transferred to a polyvinylidene difluoride (PVDF) membrane in 10 mM CAPS/10% methanol buffer (pH 11). ECL Western blot analyses were performed as described previously  using the following antibodies: Anti-RNAPII (A300-653A), anti-Ser-2 (A300-654A), and anti-Ser-5 (A300-655A) rabbit polyclonal antibodies were obtained from Bethyl.
Total RNA was isolated from cells using QIAshredder and Rneasy Mini Kit from Qiagen. Northern Blots were performed as previously described .
Affymetrix microarray hybridization, quantitation and hierarchical cluster analysis, and visualization
Global analysis of gene expression was performed using Affymetrix Human Gene 1.0 ST microarrays, which contains probe for 28,869 non-redundant transcripts. RNA was labeled and hybridized to microarrays at the University of Pennsylvania Microarray Facility (U. Penn MF) following manufacturer directions. Microarray intensity values were normalized using the Affymetrix Expression Console Software. The average of log2 ratios was calculated to represent average gene expression levels among replicate arrays. Hierarchical cluster analysis was performed using Cluster version 3.0 software with average linkage  and visualized with Java TreeView, version 1.0.13 as in .
Availability of supporting data
Microarray expression data will be deposited in the GEO database upon manuscript acceptance.
Cyclin Dependent Kinase 9
DRB Sensitivity Inducing Factor
Human Telomerase Reverse Transcriptase
Negative Elongation factor
Positive Transcription Elongation Factor b
RNA polymerase II.
Garriga J, Graña X: Cellular control of gene expression by T-type cyclin/CDK9 complexes. Gene. 2004, 337: 15-23.
Kohoutek J: P-TEFb- the final frontier. Cell Div. 2009, 4: 19-10.1186/1747-1028-4-19.
Peterlin BM, Price DH: Controlling the elongation phase of transcription with P-TEFb. Mol Cell. 2006, 23: 297-305. 10.1016/j.molcel.2006.06.014.
Garriga J, Segura E, Mayol X, Grubmeyer C, Graña X: Phosphorylation site specificity of the CDC2-related kinase PITALRE. Biochem J. 1996, 320: 983-989.
Phatnani HP, Greenleaf AL: Phosphorylation and functions of the RNA polymerase II CTD. Genes Dev. 2006, 20: 2922-2936. 10.1101/gad.1477006.
Garriga J, Xie H, Obradovic Z, Graña X: Selective control of gene expression by CDK9 in human cells. J Cell Physiol. 2010, 222: 200-208. 10.1002/jcp.21938.
Keskin H, Garriga J, Georlette D, Graña X: Complex effects of flavopiridol on the expression of primary response genes. Cell Div. 2012, 7: 11-10.1186/1747-1028-7-11.
Biglione S, Byers SA, Price JP, Nguyen VT, Bensaude O, Price DH, Maury W: Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex. Retrovirology. 2007, 4: 47-10.1186/1742-4690-4-47.
Klebl B, Choidas A: CDK9/cyclin T1: a host cell target for antiretroviral therapy. Futur Virol. 2006, 1: 317-330. 10.2217/174607188.8.131.527.
Salerno D, Hasham MG, Marshall R, Garriga J, Tsygankov AY, Graña X: Direct inhibition of CDK9 blocks HIV-1 replication without preventing T-cell activation in primary human peripheral blood lymphocytes. Gene. 2007, 405: 65-78. 10.1016/j.gene.2007.09.010.
Sano M, Schneider MD: Cyclin-dependent kinase-9: an RNAPII kinase at the nexus of cardiac growth and death cascades. Circ Res. 2004, 95: 867-876. 10.1161/01.RES.0000146675.88354.04.
Shilatifard A, Conaway JW, Conaway RC: Mechanism and regulation of transcriptional elongation and termination by RNA polymerase II. Curr Opin Genet Dev. 1997, 7: 199-204. 10.1016/S0959-437X(97)80129-3.
Wang S, Fischer PM: Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology. Trends Pharmacol Sci. 2008, 29: 302-313. 10.1016/j.tips.2008.03.003.
Smith E, Lin C, Shilatifard A: The super elongation complex (SEC) and MLL in development and disease. Genes Dev. 25: 661-672.
Lam LT, Pickeral OK, Peng AC, Rosenwald A, Hurt EM, Giltnane JM, Averett LM, Zhao H, Davis RE, Sathyamoorthy M, Wahl LM, Harris ED, Mikovits JA, Monks AP, Hollingshead MG, Sausville EA, Staudtl LM: Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol. 2001, 2 (10): RESEARCH0041.1–0041.11
Lü X, Burgan WE, Cerra MA, Chuang EY, Tsai MH, Tofilon PJ, Camphausen K: Transcriptional signature of flavopiridol-induced tumor cell death. Mol Cancer Ther. 2004, 3: 861-872.
Kohoutek J, Li Q, Blazek D, Luo Z, Jiang H, Peterlin BM: Cyclin T2 is essential for mouse embryogenesis. Mol Cell Biol. 2009, 29: 3280-3285. 10.1128/MCB.00172-09.
Yu DS, Cortez D: A role for cdk9-cyclin k in maintaining genome integrity. Cell Cycle. 2011, 10: 28-32. 10.4161/cc.10.1.14364.
Yu W, Wang Y, Shaw CA, Qin XF, Rice AP: Induction of the HIV-1 Tat co-factor cyclin T1 during monocyte differentiation is required for the regulated expression of a large portion of cellular mRNAs. Retrovirology. 2006, 3: 32-10.1186/1742-4690-3-32.
Schmerwitz UK, Sass G, Khandoga AG, Joore J, Mayer BA, Berberich N, Totzke F, Krombach F, Tiegs G, Zahler S, Vollmar AM, Fürst R: Flavopiridol protects against inflammation by attenuating leukocyte-endothelial interaction via inhibition of cyclin-dependent kinase 9. Arterioscler Thromb Vasc Biol. 2011, 31: 280-288. 10.1161/ATVBAHA.110.213934.
Hartman ZC, Kiang A, Everett RS, Serra D, Yang XY, Clay TM, Amalfitano A: Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo. J Virol. 2007, 81: 1796-1812. 10.1128/JVI.01936-06.
Sotillo E, Garriga J, Kurimchak A, Graña X: Cyclin E and SV40 small T antigen cooperate to bypass quiescence and contribute to transformation by activating CDK2 in human fibroblasts. J Biol Chem. 2008, 283: 11280-11292. 10.1074/jbc.M709055200.
Sotillo E, Garriga J, Padgaonkar A, Kurimchak A, Cook J, Graña X: Coordinated activation of the origin licensing factor CDC6 and CDK2 in resting human fibroblasts expressing SV40 small T antigen and cyclin E. J Biol Chem. 2009, 284: 14126-14135. 10.1074/jbc.M900687200.
He N, Pezda AC, Zhou Q: Modulation of a P-TEFb functional equilibrium for the global control of cell growth and differentiation. Mol Cell Biol. 2006, 26: 7068-7076. 10.1128/MCB.00778-06.
Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA: Creation of human tumour cells with defined genetic elements. Nature. 1999, 400: 464-468. 10.1038/22780.
Eisen MB, Spellman PT, Brown PO, Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998, 95: 14863-14868. 10.1073/pnas.95.25.14863.
We thank Alison Kurimchak for critically reading the manuscript and Matteo Cesaroni for statistical analysis. This work was supported, in whole or in part, by National Institutes of Health Grant MH083585 to XG. This work was also supported by a grant from the Pennsylvania Department of Health to X.G.
The authors’ declare that they have no competing interests.
JG and XG. Performed cell treatments and microarray experiments, analyzed the data and wrote the manuscript. Both authors read and approved the final manuscript.
Electronic supplementary material
Additional file 2: Figure S2: Ectopic expression of P-TEFb subunits (cyclin T1 and CDK9) resulted in the marked upregulation of a small subset of genes highly enriched with interferon response genes. Ingenuity Pathway Analysis (IPA) was performed with the set of genes upregulated in BJ-TERT cells ectopically expressing cyclin T1 and CDK9 as compared to cells transduced with the Ad-Cre control virus. Genes involved in cell-immediate immune response and humoral response are highly enriched (A). IPA Network analysis of the upregulated genes in BJ-Tert fibroblasts ectopically expressing Cyclin T1 and CDK9 identified the interferon network, which shows upregulation of multiple interferon response genes. (JPEG 566 KB)
About this article
Cite this article
Garriga, J., Graña, X. CDK9 inhibition strategy defines distinct sets of target genes. BMC Res Notes 7, 301 (2014). https://doi.org/10.1186/1756-0500-7-301
- RNA polymerase II
- Control of gene expression